Celecoxib inhibits ureteral contractility and prostanoid release

Travis Jerde, Jamie L. Calamon-Dixon, Dale E. Bjorling, Stephen Y. Nakada

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

To evaluate the efficacy and potency of clinically available celecoxib for inhibition of ureteral contractility and prostanoid release. We have previously reported that the selective cyclooxygenase (COX)-2 inhibitor NS-398 inhibits ureteral contractility. We evaluated the release of prostaglandin (PG) E 2, F, D2, thromboxane B2 (a thromboxane2 metabolite), and 6-keto-PGF (a prostacyclin metabolite) by gas chromatography-mass spectrometry from porcine ureters in the presence and absence of tumor necrosis factor-alpha (TNF-α), a putative cyclooxygenase (COX)-2 inducer. PGE2 and PGF were the prostanoids released in greatest quantity in response to TNF-α. We subsequently measured spontaneous contractility and prostanoid release in porcine ureters treated with 0.1, 1.0, or 10 μM concentrations of indomethacin (nonselective COX inhibitor), NS-398, celecoxib, or 0.1% dimethyl sulfoxide (vehicle) for 2 hours. Ureteral contractility and prostanoid release were measured every 15 minutes after the addition of the various compounds. We also treated ureters with 10 ng/mL TNF-α and all three COX inhibitors or dimethyl sulfoxide for 2 and 4 hours and measured the PGE2 and PGF release. Celecoxib, indomethacin, and NS-398 inhibited ureteral contractility and prostanoid release with similar efficacy and potency. All three compounds also reduced TNF-α-induced prostanoid release to control levels at concentrations as low as 0.1 μM. Our data have indicated that celecoxib and indomethacin inhibit PG release by the ureter to a similar degree, even in the presence of COX-2 induction. Animal experiments and clinical trials evaluating the safety and efficacy of celecoxib for the treatment of symptomatic ureteral obstruction are warranted.

Original languageEnglish (US)
Pages (from-to)185-190
Number of pages6
JournalUrology
Volume65
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Celecoxib
Prostaglandins
Ureter
Tumor Necrosis Factor-alpha
Indomethacin
Dinoprost
Cyclooxygenase Inhibitors
Cyclooxygenase 2
Dimethyl Sulfoxide
Dinoprostone
Swine
Ureteral Obstruction
Thromboxane B2
Cyclooxygenase 2 Inhibitors
Epoprostenol
Prostaglandins E
Gas Chromatography-Mass Spectrometry

ASJC Scopus subject areas

  • Urology

Cite this

Jerde, T., Calamon-Dixon, J. L., Bjorling, D. E., & Nakada, S. Y. (2005). Celecoxib inhibits ureteral contractility and prostanoid release. Urology, 65(1), 185-190. https://doi.org/10.1016/j.urology.2004.08.057

Celecoxib inhibits ureteral contractility and prostanoid release. / Jerde, Travis; Calamon-Dixon, Jamie L.; Bjorling, Dale E.; Nakada, Stephen Y.

In: Urology, Vol. 65, No. 1, 01.2005, p. 185-190.

Research output: Contribution to journalArticle

Jerde, T, Calamon-Dixon, JL, Bjorling, DE & Nakada, SY 2005, 'Celecoxib inhibits ureteral contractility and prostanoid release', Urology, vol. 65, no. 1, pp. 185-190. https://doi.org/10.1016/j.urology.2004.08.057
Jerde, Travis ; Calamon-Dixon, Jamie L. ; Bjorling, Dale E. ; Nakada, Stephen Y. / Celecoxib inhibits ureteral contractility and prostanoid release. In: Urology. 2005 ; Vol. 65, No. 1. pp. 185-190.
@article{89a5dabab608498aafa1c035a5878d3f,
title = "Celecoxib inhibits ureteral contractility and prostanoid release",
abstract = "To evaluate the efficacy and potency of clinically available celecoxib for inhibition of ureteral contractility and prostanoid release. We have previously reported that the selective cyclooxygenase (COX)-2 inhibitor NS-398 inhibits ureteral contractility. We evaluated the release of prostaglandin (PG) E 2, F2α, D2, thromboxane B2 (a thromboxane2 metabolite), and 6-keto-PGF1α (a prostacyclin metabolite) by gas chromatography-mass spectrometry from porcine ureters in the presence and absence of tumor necrosis factor-alpha (TNF-α), a putative cyclooxygenase (COX)-2 inducer. PGE2 and PGF2α were the prostanoids released in greatest quantity in response to TNF-α. We subsequently measured spontaneous contractility and prostanoid release in porcine ureters treated with 0.1, 1.0, or 10 μM concentrations of indomethacin (nonselective COX inhibitor), NS-398, celecoxib, or 0.1{\%} dimethyl sulfoxide (vehicle) for 2 hours. Ureteral contractility and prostanoid release were measured every 15 minutes after the addition of the various compounds. We also treated ureters with 10 ng/mL TNF-α and all three COX inhibitors or dimethyl sulfoxide for 2 and 4 hours and measured the PGE2 and PGF2α release. Celecoxib, indomethacin, and NS-398 inhibited ureteral contractility and prostanoid release with similar efficacy and potency. All three compounds also reduced TNF-α-induced prostanoid release to control levels at concentrations as low as 0.1 μM. Our data have indicated that celecoxib and indomethacin inhibit PG release by the ureter to a similar degree, even in the presence of COX-2 induction. Animal experiments and clinical trials evaluating the safety and efficacy of celecoxib for the treatment of symptomatic ureteral obstruction are warranted.",
author = "Travis Jerde and Calamon-Dixon, {Jamie L.} and Bjorling, {Dale E.} and Nakada, {Stephen Y.}",
year = "2005",
month = "1",
doi = "10.1016/j.urology.2004.08.057",
language = "English (US)",
volume = "65",
pages = "185--190",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Celecoxib inhibits ureteral contractility and prostanoid release

AU - Jerde, Travis

AU - Calamon-Dixon, Jamie L.

AU - Bjorling, Dale E.

AU - Nakada, Stephen Y.

PY - 2005/1

Y1 - 2005/1

N2 - To evaluate the efficacy and potency of clinically available celecoxib for inhibition of ureteral contractility and prostanoid release. We have previously reported that the selective cyclooxygenase (COX)-2 inhibitor NS-398 inhibits ureteral contractility. We evaluated the release of prostaglandin (PG) E 2, F2α, D2, thromboxane B2 (a thromboxane2 metabolite), and 6-keto-PGF1α (a prostacyclin metabolite) by gas chromatography-mass spectrometry from porcine ureters in the presence and absence of tumor necrosis factor-alpha (TNF-α), a putative cyclooxygenase (COX)-2 inducer. PGE2 and PGF2α were the prostanoids released in greatest quantity in response to TNF-α. We subsequently measured spontaneous contractility and prostanoid release in porcine ureters treated with 0.1, 1.0, or 10 μM concentrations of indomethacin (nonselective COX inhibitor), NS-398, celecoxib, or 0.1% dimethyl sulfoxide (vehicle) for 2 hours. Ureteral contractility and prostanoid release were measured every 15 minutes after the addition of the various compounds. We also treated ureters with 10 ng/mL TNF-α and all three COX inhibitors or dimethyl sulfoxide for 2 and 4 hours and measured the PGE2 and PGF2α release. Celecoxib, indomethacin, and NS-398 inhibited ureteral contractility and prostanoid release with similar efficacy and potency. All three compounds also reduced TNF-α-induced prostanoid release to control levels at concentrations as low as 0.1 μM. Our data have indicated that celecoxib and indomethacin inhibit PG release by the ureter to a similar degree, even in the presence of COX-2 induction. Animal experiments and clinical trials evaluating the safety and efficacy of celecoxib for the treatment of symptomatic ureteral obstruction are warranted.

AB - To evaluate the efficacy and potency of clinically available celecoxib for inhibition of ureteral contractility and prostanoid release. We have previously reported that the selective cyclooxygenase (COX)-2 inhibitor NS-398 inhibits ureteral contractility. We evaluated the release of prostaglandin (PG) E 2, F2α, D2, thromboxane B2 (a thromboxane2 metabolite), and 6-keto-PGF1α (a prostacyclin metabolite) by gas chromatography-mass spectrometry from porcine ureters in the presence and absence of tumor necrosis factor-alpha (TNF-α), a putative cyclooxygenase (COX)-2 inducer. PGE2 and PGF2α were the prostanoids released in greatest quantity in response to TNF-α. We subsequently measured spontaneous contractility and prostanoid release in porcine ureters treated with 0.1, 1.0, or 10 μM concentrations of indomethacin (nonselective COX inhibitor), NS-398, celecoxib, or 0.1% dimethyl sulfoxide (vehicle) for 2 hours. Ureteral contractility and prostanoid release were measured every 15 minutes after the addition of the various compounds. We also treated ureters with 10 ng/mL TNF-α and all three COX inhibitors or dimethyl sulfoxide for 2 and 4 hours and measured the PGE2 and PGF2α release. Celecoxib, indomethacin, and NS-398 inhibited ureteral contractility and prostanoid release with similar efficacy and potency. All three compounds also reduced TNF-α-induced prostanoid release to control levels at concentrations as low as 0.1 μM. Our data have indicated that celecoxib and indomethacin inhibit PG release by the ureter to a similar degree, even in the presence of COX-2 induction. Animal experiments and clinical trials evaluating the safety and efficacy of celecoxib for the treatment of symptomatic ureteral obstruction are warranted.

UR - http://www.scopus.com/inward/record.url?scp=12844281024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12844281024&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2004.08.057

DO - 10.1016/j.urology.2004.08.057

M3 - Article

VL - 65

SP - 185

EP - 190

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -